开窗式肾旁/肾上腹主动脉瘤修复中与肠系膜上动脉支架移植相关的解剖特征
单中心回顾性分析2012年6月至2020年5月接受开窗式腔内修复(FEVAR)并使用Zenith开窗支架、涉及肠系膜上动脉(SMA)开窗或扇贝形开窗的127例肾旁/肾上腹主动脉瘤患者,比较SMA支架移植、未支架开窗与扇贝形开窗三组的结局与解剖差异。SMA支架患者肾下颈及SMA下颈更短。
要点
- SMA支架组手术时间335.5±16.4分钟,长于未支架开窗组265.0±12.8分钟和扇贝形开窗组269.0±12.7分钟(P<.001)。
- SMA支架组输血率33%,高于未支架开窗组8%和扇贝形开窗组18%(P=.01)。
- 三组总体死亡率24% vs 21% vs 18%(P=.82)、30天死亡率5% vs 3% vs 3%(P=.80)无显著差异。
核心结论
- 尽管增加了技术复杂性,SMA支架移植使肾旁和肾上腹主动脉瘤患者能够接受FEVAR,且技术成功率高,未增加死亡、主要不良事件、III型内漏或再干预风险。
研究设计与样本
- 单机构回顾性分析,经机构审查委员会批准,纳入2012年6月至2020年5月接受Zenith开窗支架FEVAR并使用SMA扇贝形开窗或大开窗(伴或不伴SMA支架移植)的患者。
- 共203例动脉瘤接受Zenith开窗支架修复,127例纳入分析,其中55例SMA支架移植开窗、38例未支架SMA开窗、34例SMA扇贝形开窗。
主要发现
- 所有患者均获得技术成功。
- SMA支架组手术时间335.5±16.4分钟 vs 未支架开窗组265.0±12.8分钟 vs 扇贝形开窗组269.0±12.7分钟(P<.001),SMA支架组更长。
- SMA支架组输血率33% vs 未支架开窗组8% vs 扇贝形开窗组18%(P=.01),SMA支架组更高。
- 透视时间65.4±3.76分钟 vs 58.3±3.94分钟 vs 51.4±4.75分钟(P=.05),造影剂体积92.2±5.17 mL vs 87.1±6.73 mL vs 93.1±5.89 mL(P=.84),三组间无显著差异。
- SMA支架组肾下颈长度1.73±1.18 mm vs 未支架开窗组4.92±1.16 mm vs 扇贝形开窗组6.28±1.42 mm(P=.03),SMA支架组更短;SMA下颈长度10.3±1.39 mm vs 23.9±1.24 mm vs 26.8±1.67 mm(P<.001),SMA支架组更短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: According to the instructions for use, fenestrated endovascular aortic aneurysm repair (FEVAR) with the Zenith fenestrated endograft (ZFEN; Cook Medical, Bloomington, Ind) requires ≥4 mm of nonaneurysmal infrarenal neck length, and superior mesenteric artery (SMA) stenting is optional. In the present study, we evaluated the outcomes of FEVAR with SMA stent grafting relative to SMA scallops or unstented fenestrations and their anatomic differences. METHODS: We performed a single-institution retrospective analysis of patients who had undergone FEVAR with an SMA scallop or large fenestration with and without SMA stent grafting from June 2012 to May 2020 after institutional review board approval. RESULTS: Of the 203 aneurysms repaired with ZFENs, 127 were included in our analysis. Of these 127 aneurysms, 55 had stent grafted SMA fenestrations, 38 unstented SMA fenestrations, and 34 SMA scallops. Technical success was achieved in all patients. The operative times were longer (335.5 ± 16.4 minutes vs 265.0 ± 12.8 minutes vs 269.0 ± 12.7 minutes; P < .001) and the transfusion rates were higher (33% vs 8% vs 18%; P = .01) in the SMA stent graft group. However, the fluoroscopy time (65.4 ± 3.76 minutes vs 58.3 ± 3.94 minutes vs 51.4 ± 4.75 minutes; P = .05) and contrast volume (92.2 ± 5.17 mL vs 87.1 ± 6.73 mL vs 93.1 ± 5.89 mL; P = .84) were not significantly different. Anatomically, the patients who had undergone FEVAR with a ZFEN and SMA stent grafting had had shorter infrarenal neck (1.73 ± 1.18 mm vs 4.92 ± 1.16 mm vs 6.28 ± 1.42 mm; P = .03) and infra-SMA neck (10.3 ± 1.39 mm vs 23.9 ± 1.24 mm vs 26.8 ± 1.67 mm; P < .001) lengths. In the SMA stent graft group, one patient had developed small bowel necrosis after embolization of an intraoperatively perforated jejunal branch and two had developed colonic ischemia of unclear etiology with patent SMA stent grafts found on imaging. Endograft migration and SMA occlusion with bowel ischemia occurred in one patient in the SMA fenestration group. Overall mortality (24% vs 21% vs 18%; P = .82) and 30-day mortality (5% vs 3% vs 3%; P = .80) were comparable between the three groups. In addition, the incidence of type III endoleak (5% vs 3% vs 3%; P = .45) and the need for reintervention (20% vs 18% vs 12%; P = .60) were similar across all three groups. The mean follow-up duration was longer for the SMA scallop group, which can be attributed to 82% of these occurring in the first one half of the study period. CONCLUSIONS: Despite the added technical complexity, SMA stenting enabled FEVAR in patients with pararenal and suprarenal aneurysms with high rates of technical success and no increased risk of mortality, major adverse events, type III endoleaks, or reintervention.
引用
- Jammeh ML, Sanchez LA, Ohman JW, et al. Anatomic characteristics associated with superior mesenteric artery stent graft placement during fenestrated para/suprarenal aneurysm repair. J Vasc Surg. 2022. PMID: 35085751. doi:10.1016/j.jvs.2022.01.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。